The latest investment follows the $7 million that the company raised last week.
Biopharmaceutical company Kamada Ltd. (TASE:KMDA) today announced that it had expanded its latest round of fund raising with a NIS 6 million investment from Meitav Provident and Pension Fund Ltd. and from Meitav Mishan Provident Fund Management Ltd.
Last week Kamada reported that it had raised $7million from its founder Ralph Hahn and investment group UDT Med Holdings and that it was open to an additional $15 million in investments by June.
Kamada CEO David Tsur said that the company was conducting a kind of road show to Israeli institutional investors in order to raise investment to fund its upcoming and final clinical trial before marketing its Alpha-1 Antitrypsin (AAT) product for treating respiratory diseases.
Published by Globes [online], Israel business news - www.globes-online.com - on May 10, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009